Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk

A nested-case-control study and a pooled meta-analysis

Debora Macis, Patrick Maisonneuve, Harriet Johansson, Bernardo Bonanni, Edoardo Botteri, Simona Iodice, Barbara Santillo, Silvana Penco, Giacomo Gucciardo, Giuseppe D'Aiuto, Marco Rosselli Del Turco, Marinella Amadori, Alberto Costa, Andrea Decensi

Research output: Contribution to journalArticle

48 Citations (Scopus)

Abstract

Background: A reduced activity of methylenetetrahydrofolate reductase (MTHFR) due to frequent C677T polymorphism affects DNA synthesis, repair and methylation and may be implicated in breast cancer risk. Methods: We conducted a nested case-control study within a phase III prevention trial of tamoxifen. After a median follow-up of 81.2 months, 79 of the 5,408 hysterectomised women aged 35-70 years, who had received either tamoxifen 20 mg/day or placebo for 5 years, developed breast cancer. A total of 46 breast cancer cases and 80 unaffected controls matched to treatment allocation, years from randomization (±2 years) and age at randomization (±5 years), underwent genotyping for MTHFR C677T polymorphism using real time PCR. Results: The MTHFR 677 genotype frequencies for CC, CT, TT in breast cancer cases were 30%, 44% and 26%, respectively, and 35%, 51%, 14% in controls. We observed a borderline significant odds ratio of 2.51 (95% CI, 0.96-6.55) of breast cancer in subjects with 677TT genotype, with no further association after stratifying for age and treatment group. A meta-analysis of 18 studies, including our own, showed an increased risk of breast cancer in premenopausal women with 677TT genotype, with an odds ratio of 1.42 (95% CI, 1.02-1.98). Conclusions: Our study lends support to a positive association between the MTHFR variant homozygous allele 677TT and breast cancer risk. Additional studies are warranted to provide further insight into the role of folate metabolism deficiency and breast cancer.

Original languageEnglish
Pages (from-to)263-271
Number of pages9
JournalBreast Cancer Research and Treatment
Volume106
Issue number2
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Meta-Analysis
Case-Control Studies
Breast Neoplasms
Genotype
Tamoxifen
Random Allocation
Odds Ratio
DNA Methylation
Folic Acid
DNA Repair
Real-Time Polymerase Chain Reaction
Age Groups
Alleles
Placebos
Therapeutics

Keywords

  • Meta-analysis
  • Methylenetetrahydrofolate reductase
  • Nested case-control study

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk : A nested-case-control study and a pooled meta-analysis. / Macis, Debora; Maisonneuve, Patrick; Johansson, Harriet; Bonanni, Bernardo; Botteri, Edoardo; Iodice, Simona; Santillo, Barbara; Penco, Silvana; Gucciardo, Giacomo; D'Aiuto, Giuseppe; Rosselli Del Turco, Marco; Amadori, Marinella; Costa, Alberto; Decensi, Andrea.

In: Breast Cancer Research and Treatment, Vol. 106, No. 2, 12.2007, p. 263-271.

Research output: Contribution to journalArticle

Macis, D, Maisonneuve, P, Johansson, H, Bonanni, B, Botteri, E, Iodice, S, Santillo, B, Penco, S, Gucciardo, G, D'Aiuto, G, Rosselli Del Turco, M, Amadori, M, Costa, A & Decensi, A 2007, 'Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: A nested-case-control study and a pooled meta-analysis', Breast Cancer Research and Treatment, vol. 106, no. 2, pp. 263-271. https://doi.org/10.1007/s10549-006-9491-6
Macis, Debora ; Maisonneuve, Patrick ; Johansson, Harriet ; Bonanni, Bernardo ; Botteri, Edoardo ; Iodice, Simona ; Santillo, Barbara ; Penco, Silvana ; Gucciardo, Giacomo ; D'Aiuto, Giuseppe ; Rosselli Del Turco, Marco ; Amadori, Marinella ; Costa, Alberto ; Decensi, Andrea. / Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk : A nested-case-control study and a pooled meta-analysis. In: Breast Cancer Research and Treatment. 2007 ; Vol. 106, No. 2. pp. 263-271.
@article{b62738a2d83546768ccbbdf466c86c8e,
title = "Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: A nested-case-control study and a pooled meta-analysis",
abstract = "Background: A reduced activity of methylenetetrahydrofolate reductase (MTHFR) due to frequent C677T polymorphism affects DNA synthesis, repair and methylation and may be implicated in breast cancer risk. Methods: We conducted a nested case-control study within a phase III prevention trial of tamoxifen. After a median follow-up of 81.2 months, 79 of the 5,408 hysterectomised women aged 35-70 years, who had received either tamoxifen 20 mg/day or placebo for 5 years, developed breast cancer. A total of 46 breast cancer cases and 80 unaffected controls matched to treatment allocation, years from randomization (±2 years) and age at randomization (±5 years), underwent genotyping for MTHFR C677T polymorphism using real time PCR. Results: The MTHFR 677 genotype frequencies for CC, CT, TT in breast cancer cases were 30{\%}, 44{\%} and 26{\%}, respectively, and 35{\%}, 51{\%}, 14{\%} in controls. We observed a borderline significant odds ratio of 2.51 (95{\%} CI, 0.96-6.55) of breast cancer in subjects with 677TT genotype, with no further association after stratifying for age and treatment group. A meta-analysis of 18 studies, including our own, showed an increased risk of breast cancer in premenopausal women with 677TT genotype, with an odds ratio of 1.42 (95{\%} CI, 1.02-1.98). Conclusions: Our study lends support to a positive association between the MTHFR variant homozygous allele 677TT and breast cancer risk. Additional studies are warranted to provide further insight into the role of folate metabolism deficiency and breast cancer.",
keywords = "Meta-analysis, Methylenetetrahydrofolate reductase, Nested case-control study",
author = "Debora Macis and Patrick Maisonneuve and Harriet Johansson and Bernardo Bonanni and Edoardo Botteri and Simona Iodice and Barbara Santillo and Silvana Penco and Giacomo Gucciardo and Giuseppe D'Aiuto and {Rosselli Del Turco}, Marco and Marinella Amadori and Alberto Costa and Andrea Decensi",
year = "2007",
month = "12",
doi = "10.1007/s10549-006-9491-6",
language = "English",
volume = "106",
pages = "263--271",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "2",

}

TY - JOUR

T1 - Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk

T2 - A nested-case-control study and a pooled meta-analysis

AU - Macis, Debora

AU - Maisonneuve, Patrick

AU - Johansson, Harriet

AU - Bonanni, Bernardo

AU - Botteri, Edoardo

AU - Iodice, Simona

AU - Santillo, Barbara

AU - Penco, Silvana

AU - Gucciardo, Giacomo

AU - D'Aiuto, Giuseppe

AU - Rosselli Del Turco, Marco

AU - Amadori, Marinella

AU - Costa, Alberto

AU - Decensi, Andrea

PY - 2007/12

Y1 - 2007/12

N2 - Background: A reduced activity of methylenetetrahydrofolate reductase (MTHFR) due to frequent C677T polymorphism affects DNA synthesis, repair and methylation and may be implicated in breast cancer risk. Methods: We conducted a nested case-control study within a phase III prevention trial of tamoxifen. After a median follow-up of 81.2 months, 79 of the 5,408 hysterectomised women aged 35-70 years, who had received either tamoxifen 20 mg/day or placebo for 5 years, developed breast cancer. A total of 46 breast cancer cases and 80 unaffected controls matched to treatment allocation, years from randomization (±2 years) and age at randomization (±5 years), underwent genotyping for MTHFR C677T polymorphism using real time PCR. Results: The MTHFR 677 genotype frequencies for CC, CT, TT in breast cancer cases were 30%, 44% and 26%, respectively, and 35%, 51%, 14% in controls. We observed a borderline significant odds ratio of 2.51 (95% CI, 0.96-6.55) of breast cancer in subjects with 677TT genotype, with no further association after stratifying for age and treatment group. A meta-analysis of 18 studies, including our own, showed an increased risk of breast cancer in premenopausal women with 677TT genotype, with an odds ratio of 1.42 (95% CI, 1.02-1.98). Conclusions: Our study lends support to a positive association between the MTHFR variant homozygous allele 677TT and breast cancer risk. Additional studies are warranted to provide further insight into the role of folate metabolism deficiency and breast cancer.

AB - Background: A reduced activity of methylenetetrahydrofolate reductase (MTHFR) due to frequent C677T polymorphism affects DNA synthesis, repair and methylation and may be implicated in breast cancer risk. Methods: We conducted a nested case-control study within a phase III prevention trial of tamoxifen. After a median follow-up of 81.2 months, 79 of the 5,408 hysterectomised women aged 35-70 years, who had received either tamoxifen 20 mg/day or placebo for 5 years, developed breast cancer. A total of 46 breast cancer cases and 80 unaffected controls matched to treatment allocation, years from randomization (±2 years) and age at randomization (±5 years), underwent genotyping for MTHFR C677T polymorphism using real time PCR. Results: The MTHFR 677 genotype frequencies for CC, CT, TT in breast cancer cases were 30%, 44% and 26%, respectively, and 35%, 51%, 14% in controls. We observed a borderline significant odds ratio of 2.51 (95% CI, 0.96-6.55) of breast cancer in subjects with 677TT genotype, with no further association after stratifying for age and treatment group. A meta-analysis of 18 studies, including our own, showed an increased risk of breast cancer in premenopausal women with 677TT genotype, with an odds ratio of 1.42 (95% CI, 1.02-1.98). Conclusions: Our study lends support to a positive association between the MTHFR variant homozygous allele 677TT and breast cancer risk. Additional studies are warranted to provide further insight into the role of folate metabolism deficiency and breast cancer.

KW - Meta-analysis

KW - Methylenetetrahydrofolate reductase

KW - Nested case-control study

UR - http://www.scopus.com/inward/record.url?scp=34250900256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34250900256&partnerID=8YFLogxK

U2 - 10.1007/s10549-006-9491-6

DO - 10.1007/s10549-006-9491-6

M3 - Article

VL - 106

SP - 263

EP - 271

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 2

ER -